Singapore| No | Meta Name | Value |
| 1 | viewport | width=device-width, initial-scale=1, shrink-to-fit=no |
| 2 | author | Bahin-Bhau Pvt. Ltd. |
| Keyword | Position | Traffic % | Keyword Cost | Traffic Cost | Results |
| iovance pdufa | 72 | 0 | 0 | 0 | 91 |
| rayzebio acquisition | 60 | 0 | 0 | 0 | 62200 |
| danaher spin off 2023 | 58 | 0 | 0 | 0 | 32800 |
| eppendorf group | 63 | 0 | 2.25 | 0 | 17500000 |
| marc casper thermo | 39 | 0 | 0 | 0 | 139000 |
| da-1726 | 26 | 0 | 0 | 0 | 23100000 |
| profound genmab | 56 | 0 | 0 | 0 | 13300 |
| icp-332 | 52 | 0 | 0 | 0 | 10500000 |
| iovance bla | 72 | 0 | 0 | 0 | 6320 |
| lb54640 | 44 | 0 | 0 | 0 | 11300 |
| perpetual medicines | 21 | 0 | 0 | 0 | 1940000 |
| autx | 94 | 0 | 0 | 0 | 84800 |
| quten research institute llc | 56 | 0 | 2.1800000667572 | 0 | 4030 |
| profound bio genmab | 61 | 0 | 0 | 0 | 9200 |
| somalogic acquisition | 59 | 0 | 0 | 0 | 74900 |
| marc casper thermo | 83 | 0 | 0 | 0 | 139000 |
| 10x nanostring lawsuit | 87 | 0 | 0 | 0 | 20300 |
| ari bousbib | 16 | 100 | 0 | 0 | 22800 |
| norman schwartz | 55 | 0 | 0 | 0 | 8790000 |
| leap-008 | 85 | 0 | 8.1300001144409 | 0 | 3150000 |
| iovance bla | 24 | 0 | 0 | 0 | 6320 |
| jacob thaysen | 53 | 0 | 0 | 0 | 34600 |
| hummingbird diagnostics | 59 | 0 | 0 | 0 | 406000 |
| epsilogen | 56 | 0 | 0 | 0 | 6070 |
| norman schwartz | 18 | 0 | 0 | 0 | 8790000 |
| No | Text |
| 1 | Biopharma - don't miss |
| 2 | Biopharma boardroom spotlight |
| 3 | From our thought leader's |
| 4 | Bio finance |
| 5 | Contract services |
| 6 | Asıa |
| 7 | Europe |
| 8 | North america |
| 9 | Emea and more |
| 10 | Biopharma ınsight |
| 11 | Products spotlight |
| 12 | Biopharma video |
| 13 | Partner content |
| 14 | Biopharma breakthrough's |
| 15 | Editor picks |
| 16 | Survey box |
| No | Text |
| 1 | Moderna secures european commission approval for first mrna rsv vaccine, mresvıa® |
| 2 | ındia's bioe3 policy: a strategic leap towards global biomanufacturing leaders***p |
| 3 | Varian ıntroduces hypersight™ ımaging extension to truebeam and edge, setting a new standard in asia pacific radiotherapy |
| 4 | Danaher korea and korea green foundation sign landmark mou to drive urban forest development and climate solutions |
| 5 | Honeywell launches hqmr to transform quality management in life sciences |
| 6 | 15 august, 2024 | thursday | news |
| 7 | 12 august, 2024 | monday | company results |
| 8 | 05 august, 2024 | monday | company results |
| 9 | 29 july, 2024 | monday | ınteraction |
| 10 | 27 august, 2024 | tuesday | news |
| 11 | 23 july, 2024 | tuesday | company results |
| 12 | 22 august, 2024 | thursday | news |
| 13 | 21 august, 2024 | wednesday | news |
| 14 | Maximize time for ınnovation: strategies for reducing non-core tasks in the lab |
| 15 | Extractables in single-use systems used in adc manufacturing |
| 16 | Empower the next wave of pharmaceutical breakthroughs with molecule gen's aı-driven ınnovation |
| 17 | Unleash the future of drug discovery with molecule gen: your aı odyssey begins here! |
| 18 | Three ways chromatography data system software drives the lab of the future |
| 19 | Breakthrough cardiac study reveals long-term ımpact on post-transplant survival: a 2-year clinical ınvestigation advancing heart preservation |
| 20 | Thermo fisher scientific launches animal-free formula for cell therapy production scale-up |
| 21 | Lıscure biosciences' lb-p8 granted fast track designation by fda for primary sclerosing cholangitis treatment |
| 22 | Orchard ther***utics achieves landmark fda approval for lenmeldy™, pioneering gene therapy for early-onset metachromatic leukodystrophy |
| 23 | Crinetics announces positive topline results from phase 2 trial of paltusotine for the treatment of carcinoid syndrome |
| 24 | Merck's ceo belén garijo champions resilience and growth amidst 2023's market challenges, sets strategic path for sustainable success |
| 25 | Bıo sets new strategic direction on national security under leaders***p of ceo john f. crowley |
| 26 | ıcon ceo, dr. steve cutler, highlights strong performance and affirms 2024 financial guidance |
| 27 | Bio-rad's ceo, norman schwartz, antic****tes sector rebound in 2024 amid fourth quarter challenges |
| 28 | Ceo ari bousbib commends ıqvıa's resilience amidst challenging 2023 landscape |
| 29 | Gdmc charts a new course in genetic therapy ınnovation with strategic series a ınvestment |
| 30 | Poll of the week |
| 31 | Stay connected |
| No | Text |
| 1 | 28 August, 2024 | Wednesday |
| 2 | Login |
| 3 | {{ optionDetail.option }} |
External Link Count
: 7
Domain Name: BIOPHARMABOARDROOM.COM
Registry Domain ID: 2731015597_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.squarespace.domains
Registrar URL: http://domains2.squarespace.com
Updated Date: 2024-06-05T04:12:38Z
Creation Date: 2022-10-10T05:30:10Z
Registry Expiry Date: 2025-10-10T05:30:10Z
Registrar: Squarespace Domains II LLC
Registrar IANA ID: 895
Registrar Abuse Contact Email: abuse-complaints@squarespace.com
Registrar Abuse Contact Phone: +1.6466935324
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.DNS-PARKING.COM
Name Server: NS2.DNS-PARKING.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2024-08-28T02:52:35Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.